ArticleFrontiers in immunology2011
Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22.
Article in Frontiers in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis.Journal of neuroinflammation · 2026Article
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy.Clinical lymphoma, myeloma & leukemia · 2026Review
- Molecular Characterization and Expression Analysis ofBiology · 2026Article
- Glycosylation in neuroinflammation: mechanisms, implications, and therapeutic strategies for neurodegenerative diseases.Translational neurodegeneration · 2025Review
- RENBP inhibition amplifies metabolic glycan labeling efficiency of antigen-presenting cells in vitro and in vivo.Cell chemical biology · 2025Article
- Expression and functional characterization of an anti-CD22 scFv targeting B-cell malignancies.Research in pharmaceutical sciences · 2025Article
- Computational analyses to reveal the key determinants of the high malignancy level of cholangiocarcinoma.Journal of translational internal medicine · 2024Article
- Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.Cancer · 2024Review
- Review
- Elevated level of multibranched complex glycan reveals an allergic tolerance status.Clinical proteomics · 2024Article
- Lectin-Based Immunophenotyping and Whole Proteomic Profiling of CT-26 Colon Carcinoma Murine Model.International journal of molecular sciences · 2024Article
- B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis.Frontiers in immunology · 2024Article
- Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.Cancers · 2023Review
- Cell and biomaterial delivery strategies to induce immune tolerance.Advanced drug delivery reviews · 2023Review
- GL7 ligand expression defines a novel subset of CD4Mucosal immunology · 2023Article
- Cannabidiol and Cannabigerol Modify the Composition and Physicochemical Properties of Keratinocyte Membranes Exposed to UVA.International journal of molecular sciences · 2023Article
- Differential miRNA expression profiles in the bone marrow of Beagle dogs at different stages of Toxocara canis infection.BMC genomics · 2022Article
- Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors.Molecular diversity · 2022Article
- Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.Journal of the American Chemical Society · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cell antigen receptor (BCR) engagement can lead to many different physiologic outcomes. To achieve an appropriate response, the BCR signal is interpreted in the context of other stimuli and several additional receptors on the B cell surface participate in the modulation of the signal. Two members of the Siglec (sialic acid-binding immunoglobulin-like lectin) family, CD22 and Siglec-G have been shown to inhibit the BCR signal. Recent findings indicate that the ability of these two receptors to bind sialic acids might be important to induce tolerance to self-antigens. Sialylated glycans are usually absent on microbes but abundant in higher vertebrates and might therefore provide an important tolerogenic signal. Since the expression of the specific ligands for Siglec-G and CD22 is tightly regulated and since Siglecs are not only able to bind their ligands in trans but also on the same cell surface this might provide additional mechanisms to control the BCR signal. Although both Siglec-G and CD22 are expressed on B cells and are able to inhibit BCR mediated signaling, they also show unique biological functions. While CD22 is the dominant regulator of calcium signaling on conventional B2 cells and also seems to play a role on marginal zone B cells, Siglec-G exerts its function mainly on B1 cells and influences their lifespan and antibody production. Both Siglec-G and CD22 have also recently been linked to toll-like receptor signaling and may provide a link in the regulation of the adaptive and innate immune response of B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.